Analysis of 1,452 Korean Families Reveals Variants Missed by Conventional Tests
Some Cases Lead to Personalized Treatment

A large-scale domestic study has found that applying whole genome sequencing to patients with rare genetic diseases who could not be diagnosed through conventional genetic tests can identify the causative genetic variants in nearly half of the cases.


On January 30, Seoul National University Hospital announced that a research team led by Professors Jonghee Chae, Seungbok Lee, and Suyeon Kim from the Department of Clinical Genomic Medicine, together with Dr. Kohoon Seo's team from the genome analysis company 3billion, conducted whole genome sequencing on 1,452 Korean families (a total of 3,317 individuals) suspected of having rare genetic diseases. The study identified the cause of the disease in 46.2% of all families analyzed.

From the left, Jonghee Chae, Seungbok Lee, and Suyeon Kim, Professors of Clinical Genomics Medicine at Seoul National University Hospital. Seoul National University Hospital

From the left, Jonghee Chae, Seungbok Lee, and Suyeon Kim, Professors of Clinical Genomics Medicine at Seoul National University Hospital. Seoul National University Hospital

View original image

Among the 672 families in which a diagnosis was made, 14.6% had causative genetic variants identified only through whole genome sequencing. When family members were included in the analysis, the diagnostic rate was 48.5%, which was higher than the rate for testing the patient alone (41.5%).


By disease type, the diagnostic rate was relatively high for neuromuscular diseases and neurodevelopmental disorders. In 4.3% of all those tested, additional pathogenic genetic variants were found that could affect health, such as increased risk of cardiomyopathy, arrhythmia, or cancer.


Among patients whose disease cause was identified, 18.5% had long-term treatment or management plans established based on the genetic diagnosis. Personalized treatment was actually applied in clinical practice for patients with Gitelman syndrome and generalized pustular psoriasis.


The research team believes that whole genome sequencing can serve as a foundation for expanding precision medicine in the future, not only by predicting prognosis and providing family counseling for patients with rare genetic diseases, but also by enabling gene-targeted therapies.



Professor Chae stated, "We have confirmed the clinical utility of whole genome sequencing in a large patient cohort, even among those who could not be diagnosed with conventional tests," adding, "Accurate genetic diagnosis can reduce diagnostic delays and lead to early treatment and personalized management."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing